Agoracom Blog Home

Posts Tagged ‘MMJ’

« Older Entries
Newer Entries »

Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:04 AM on Monday, March 12th, 2018

15233 mcoa

  • Announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week,
  • One of the largest business-to-business trade shows in the world.

Escondido, California–(March 12, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week, one of the largest business-to-business trade shows in the world.

Convenient Hemp Mart has developed a collection of Benihemp branded, sample sized products for consumers including topicals, tinctures, and edibles packaged in 1-day, 2-day, and 30-day supplies. The target markets are convenience stores, smoke shops, gas stations and similar types of retail businesses where CBD commerce has a greater likelihood of generating sales from the impulse buyer at the register.

Convenient Hemp Mart is officially launching the Benihemp product line at ASD Market Week (www.asdonline.com) in Las Vegas, NV. ASD is a comprehensive business-to-business trade show for retail merchandise that annually hosts 45,000 buyers from over 90 countries, representing major department stores, convenience stores, gift shops, grocery stores, and other retail stores. Out of the 45,000 attending the show, 98% of the attendees have purchasing power, and the average buyer spends a total of $82,500 on product orders per show. Benihemp will be located in the lower south hall at booth SL2449.

MCOA has invested $100,000 into Benihemp in exchange for a 25% equity stake in Convenient Hemp Mart, LLC.

Donald Steinberg CEO of MCOA stated “Marijuana Company of America is excited for the opportunity to diversify product distribution into retail markets across the country. We believe in the Convenient Hemp Mart team and their ability to successfully launch Benihemp at ASD.”

“We are eagerly looking forward to the unveiling of the Benihemp brand at this ASD Marketplace event. With the ever-growing Convenience store marketplace hitting a new record of over 140 billion dollars in annual sales last year, we believe this is the perfect place to present the first industrial Hemp derived products developed specifically for this market. Our team has worked very diligently for the launch of the Benihemp brand and are all thrilled that it has finally come to life,” said Sam Girges of Benihemp.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our Benihemp Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Announces LOI With Inolife R&D to Conduct a Research Study to Evaluate Needle-Free Injection Technologies for Medical Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:53 AM on Monday, March 12th, 2018

Nlogo

  • Signed a non-binding LOI with Inolife R&D Inc.
  • To initiate a research study to evaluate applications for Inolife’s proprietary needle-free injectors in the medical cannabis industry

VANCOUVER, British Columbia, March 12, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has signed a non-binding LOI with Inolife R&D Inc. (“Inolife”), whereby Namaste and Inolife will negotiate the terms of a definitive agreement (the “Agreement”) to initiate a research study to evaluate applications for Inolife’s proprietary needle-free injectors in the medical cannabis industry. Under the terms of the LOI and proposed Agreement, Namaste will hold exclusive rights to research and distribute Inolife’s needle-free injection technologies for applications in the cannabis industry. Namaste will also participate in Inolife’s anticipated private placement by acquiring up to 10% of the shares issued under the offering. Inolife will also provide Namaste with the right to acquire up to an additional 10% of the shares issued under the offering at the same price. Additionally, Namaste will purchase up to 10% of the shares issued in connection with Inolife’s go-public transaction for approximately $250,000. Namaste believes that Inolife’s needle-free technologies could revolutionize dosage and administration of cannabis for medical purposes.

The LOI and proposed Agreement represent a strategic initiative for Namaste’s continued effort to offer innovative products to the medical cannabis market. Namaste believes that Inolife’s technology provides the most accurate and efficient method for dosing with medical cannabis. Namaste expects to work within Health Canada’s current and future cannabis regulations, when proceeding towards commercialization of pre-filled needle-free syringes. Namaste expects to commercialize the pre-filled needle-free syringes through its wholly owned subsidiary and late-stage applicant under Access to Cannabis for Medical Purposes Regulations (“ACMPR”), Cannmart Inc. The Company also expects to engage with Canadian ACMPR medical cannabis producers to co-brand medical cannabis oil, to be sold and used for applications with Inolife’s technology.

Key Terms of the LOI

  • Namaste will initiate a research study to determine the viability to use Inolife’s needle-free injectors for medical cannabis.
  • Namaste will bear all costs for research and development.
  • Namaste will participate for up to 10% of Inolife’s anticipated private placement and go-public transaction.
  • Namaste will have exclusive rights to distribute Inolife’s products for the purposes of use with medical cannabis.
  • Both parties agree to a 30-day period from the execution date of the LOI to negotiate terms of a definitive agreement and establish a protocol to proceed with a research study.

Management Commentary

Michael Wright, President and CEO of Inolife comments, “We’re very excited about the proposed partnership with Namaste. We feel that Namaste is best positioned to deliver on our strategic plan to become an innovator of delivery systems for the medical cannabis industry. We’re pleased to be the first company, in partnership with Namaste, to explore needle-free device technology in the context of medical cannabis delivery.”

Sean Dollinger, President and CEO of Namaste comments, “We are very pleased to announce this LOI and our expectation of providing research and development of this innovative technology for applications with medical cannabis. We believe that Inolife’s technology could provide the most efficient and accurate method for dosing with medical cannabis. We see a massive opportunity to revolutionize the industry by bringing this exciting technology to the medical cannabis market. We’re delighted to see that industry-leading companies like Inolife are recognizing Namaste for its value in its database, platform and brand.”

About Inolife R&D Inc.
Inolife R&D Inc. is an emerging specialty medical device company focused on developing and commercializing self-administered medical products using novel drug delivery technologies. The company was founded to take advantage of novel techniques of liquid jet and ballistics-based epidermal drug injection that we believe will improve a patient’s quality of life by making medicines easier to self-administer, work better, and remove the anxiety and inconvenience associated with hypodermic needle injections.

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors,

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

For more information about Inolife R&D Inc. and its products please visit inolifesciences.com
Michael Wright
President, CEO
Direct: 1-866-834-3777
Email: [email protected]

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces LOI With Inolife R&D to Conduct a Research Study to Evaluate Needle-Free Injection Technologies for Medical Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca $NXTTF Announces LOI With Ample Organics to Integrate and Sell Vaporizer Hardware Through Their E-Commerce Platform $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:37 AM on Thursday, March 8th, 2018

Nlogo

  • Ample Organics will offer Namaste’s product catalogue of over 5000 vaporizers and similar products to their clients via API integration
  • Namaste will provide product and warranty claim support for Ample Organics’ clients
  • Namaste will provide sales and support training to Ample Organics’ customer service team

VANCOUVER, British Columbia, March 08, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce the signing of a Hardware Supply Letter of Intent (“LOI”) with Ample Organics Inc. (“Ample Organics”), whereby Namaste and Ample Organics will integrate Namaste’s vaporizer and accessory hardware with Ample Organics’ e-commerce platform. The intention of the LOI is to allow all of Ample Organics’ customers, including their extensive client list of ACMPR Licensed Producers to access Namaste’s full range of high-quality products. This engagement represents a unique opportunity for both Ample Organics and Namaste to leverage their technology platforms to provide added value and a new revenue stream for many of Canada’s largest ACMPR Licensed Producers.

Ample Organics is Canada’s leading seed-to-sale software platform. Under the terms of the LOI, Ample Organics and Namaste will collaborate and aim to provide ACMPR Licensed Producers and their patients seamless access to the widest range of high-quality vaporizer and accessory hardware in the cannabis industry.

Key Terms of the LOI

  • Ample Organics will offer Namaste’s product catalogue of over 5000 vaporizers and similar products to their clients via API integration.
  • Namaste will provide product and warranty claim support for Ample Organics’ clients.
  • Namaste will provide sales and support training to Ample Organics’ customer service team.

Management Commentary

John X. Prentice, President and CEO of Ample Organics, comments, “Namaste has established a world leading portfolio of innovative and novel products. This partnership represents an incredible opportunity to provide additional value to our Licensed Producer clients and their patients by integrating Namaste’s products directly into the e-commerce platform used by over 200,000 patients across Canada.

Sean Dollinger, President and CEO of Namaste comments, “We are very pleased to be partnering with Ample Organics, who we believe is Canada’s largest and most innovative and trusted seed-to-sale software platform. With access to 80% of Canada’s medical cannabis patients and the country’s largest dataset, Ample Organics provides Namaste with an incredible opportunity to offer our high-quality vaporizers and accessories to Licensed Producers across the country, and for Ample Organics to provide even more value for their clients. In addition to partnering with Ample Organics on this exciting project, we are also working closely with Ample Organics’ team as it relates to our late-stage ACMPR medical cannabis “sales-only” license under our wholly owned subsidiary, Cannmart Inc., and have also identified additional opportunities for future collaborations that could be mutually beneficial for both parties. We are very excited to be working the Ample Organics and look forward to following through on this LOI with a definitive agreement.”

About Ample Organics
Ample Organics is Canada’s leading cannabis business solution, adopted by 75% of the nation’s Licensed Producers. To date, the Ample Organics platform has processed more than 680,000 orders and 12,000,000 grams of cannabis. Ample Organics makes compliance easy by tracking individual plants, from seed to consumer, and reporting every detail of the growth, production, and sales processes. With Ample Organics, data is collected at the most granular levels, offering insights that can drive business decisions and help to protect public safety. Beyond seed to sale, Ample Organics’ extended suite of products creates a complete ecosystem for cannabis businesses. From easy patient registration to cannabis-exclusive payment solutions, Ample Organics continues to evolve and release new products to provide reliable and compliant solutions for the cannabis industry.

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors,

Sean Dollinger
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

For more information about Ample Organics, please visit ampleorganics.com or contact:
Peter Slater
VP, Corporate Development
Direct: +1 (416) 262-4175
Email: [email protected]

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release

Tags: , , , , ,
Posted in All Recent Posts, Featured, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces LOI With Ample Organics to Integrate and Sell Vaporizer Hardware Through Their E-Commerce Platform $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Signs Co-development and Distribution Partnership Term Sheet $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:25 AM on Thursday, March 8th, 2018

Logo tetrabiopharma rgb web

  • Signed co-development and distribution partnership term sheet with a major specialty healthcare distributor
  • Company has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals

OTTAWA, ONTARIO–(March 8, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has signed a co-development and distribution partnership term sheet with a major specialty healthcare distributor.

The finalization of the term sheet follows Tetra’s September 20th, 2017 Letter of Intent for a co-development and distribution partnership with the same privately held company in the specialty healthcare market. The company has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to more than 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners.

Partnership highlights

  • In order to maximize both marketing and revenue impact, Tetra and its partner have agreed to launch all products at the same time, once the regulatory framework has been established by Health Canada following the legalization of cannabis. This includes cannabinoid-based as well as non-cannabinoid-based products. Both companies are confident that this strategy will solidify the brand awareness of Tetra’s partner in this new product line. The timing of the original LOI was for the commencement of revenue in Q1 2018. Tetra and its partner are now revising that date to Q4 2018.
  • Both Tetra and its partner will agree to a clinical trial plan, with Tetra owning and maintaining the right to use the data gathered from the trial(s) for its own regulatory and commercial efforts in its own, non-competitive Fields of Use.
  • Tetra will develop a line of private label products for its partner, the products will be distributed under the partner’s brand.

Management Statement

“We are very pleased to sign this term sheet as it solidifies the elements of the LOI outlined in September. We are continually striving and working hard every day to both solidify and grow Tetra as a major player in cannabinoid pharma and this is yet again a step in that direction. I am excited to continue to build on the momentum that we have going for us now and throughout 2018,” says Bernard Fortier, CEO of Tetra.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Signs Co-development and Distribution Partnership Term Sheet $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces February 2018 Sales of C$1.37M Representing a 146% Year-Over-Year Increase and Provides Update on #NamasteMD $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:55 AM on Wednesday, March 7th, 2018

Nlogo

  • February 2018 total unaudited net revenue C$1,370,442
  • 146% revenue increase in February 2018 vs. February 2017

VANCOUVER, British Columbia, March 07, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce February 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,370,442, representing a 146% revenue increase in February 2018 compared with February 2017. February is a historically low month for sales and as such, the Company is pleased with these results. Management anticipates these year-on-year growth trends to continue as the Canadian market moves towards cannabis legalization and the Company executes its strategy to expand sales in emerging markets.

The table below outlines gross sales of Namaste’s major sites and includes site traffic, conversion rates, total number of orders per site and average online basket price.

In addition to announcing its February sales, the Company is pleased to provide an update on its progress with Namaste’s medical cannabis telemedicine application, NamasteMD. During the month of February, management initiated a soft-launch of NamasteMD, which is now available on Apple and Google Android devices. The Company is pleased with initial results, having over 3,000 downloads with a 5-star rating on the Apple Store and a 4.9-star rating on Google Android. The Company, through its soft-launch of NamasteMD has also acquired 375 medical cannabis patients. The Company is now focusing on streamlining the patient acquisition process and further developing the platform. Management anticipates substantial growth in patient acquisition rates for March following a full launch of NamasteMD across the Company’s Canadian platform.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to be seeing the positive trend of monthly sales increases year-over-year. With the Cannmart license pending approval, we are very encouraged to see our hardware business growing, which should have a direct impact on our ability to expand our e-commerce platform to include the sale of cannabis products and shift our focus on aggressive acquisition of patients via NamasteMD. While the soft-launch of NamasteMD has been a success, we feel that obtaining our sales license should substantially increase our ability to convert downloaded users into patients. Our ability to provide patients with an all-inclusive e-commerce marketplace of cannabis products and services in the near term should serve to significantly increase our market share moving forward.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:
namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

 

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces February 2018 Sales of C$1.37M Representing a 146% Year-Over-Year Increase and Provides Update on #NamasteMD $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Announces Closing of Bought Deal Financing $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 10:46 AM on Monday, March 5th, 2018

Logo tetrabiopharma rgb web

  • Closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriter’s over-allotment option
  • Total of 11,500,000 units of the Corporation were sold at a price of $1.00 per Unit

OTTAWA, March 05, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX-V:TBP) (OTCQB:TBPMF), is pleased to announce it has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriter’s over-allotment option. A total of 11,500,000 units (the “Units”) of the Corporation were sold at a price of $1.00 per Unit, for aggregate gross proceeds of $11,500,00 (the “Offering”).

Each Unit consisted of one common share of the Corporation and one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one common share of the Corporation at a price of $1.30 until March 5, 2021. The Offering was underwritten by Echelon Wealth Partners Inc.

The Corporation intends to use the net proceeds from the Offering to continue the development of its clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers, to repay indebtedness of the Corporation, and for working capital and general corporate purposes.

“We are extremely pleased to have worked with Echelon Wealth Partners in this financing . As we are about to initiate our Health Canada approved phase 3 registration trial for our lead drug candidate, PPP001, for late stage cancer patients, the proceeds from this Offering will enable Tetra to continue, and potentially accelerate some of the key development projects in our pipeline.  This is another milestone in working towards becoming the first biopharmaceutical company in the world to get a smokable dried cannabis product approved as a prescription drug by Health Canada, the FDA and other regulatory agencies around the world,” stated Bernard Fortier, CEO of Tetra.

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“) or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

This press release does not constitute an offer to sell or a solicitation of any offer to buy the securities in the United States, in any province or territory of Canada or in any other jurisdiction. There shall be no sale of the securities in any jurisdiction in which an offer to sell, a solicitation of an offer to buy or sale would be unlawful.

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

For further information, please contact Tetra Bio-Pharma Inc.
Bernard Lessard, MBA, CPA, CMA
Chief Financial Officer
[email protected]
438 899 7575 ext.207

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tags: , , ,
Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces Closing of Bought Deal Financing $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca $NXTTF Submits Health Canada ACMPR Affirmation of Readiness $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:49 AM on Monday, March 5th, 2018

Nlogo

  • Company’s wholly owned subsidiary, Cannmart Inc. has submitted its Affirmation of Readiness and video evidence package
  • Purpose of the AOR is to provide evidence to Health Canada that Cannmart has completed construction and fit-up of the facility as per the application
  • AOR represents a significant milestone for the Company in completion of the construction of Cannmart’s facility

VANCOUVER, British Columbia, March 05, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) has submitted its Affirmation of Readiness (“AOR”) and video evidence package to Health Canada. Cannmart is a late-stage applicant for a medical cannabis “sales-only” license under Canada’s Access to Cannabis for Medical Purposes Regulation (“ACMPR”). The purpose of the AOR is to provide evidence to Health Canada that Cannmart has completed construction and fit-up of the facility as per the application. Having submitted the AOR, the Company anticipates Health Canada’s review of the evidence package in due course and the issuance of its ACMPR sales license shortly thereafter. The AOR represents a significant milestone for the Company in completion of the construction of Cannmart’s facility.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have completed construction of Cannmart and submission of the AOR. Namaste is looking forward to launching Cannmart and following through with our strategy to become Canada’s leading innovator in medical cannabis online retail. Thank you to the management team at Cannmart for seeing this project through to completion and we’re looking forward to receiving follow up from Health Canada soon.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Submits Health Canada ACMPR Affirmation of Readiness $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Announces the Completion of GrowPros Transaction $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:16 PM on Thursday, February 22nd, 2018

Logo tetrabiopharma rgb web

 

 

  • Completion of the sale of its shares of GrowPros MMP Inc. (“GrowPros”) to North Bud Farms Inc.
  • Cash proceeds will be used to further strengthen Tetra’s balance sheet and, most importantly, allow the Company to focus its activities on drug development and clinical trials of its pharmaceutical business.

OTTAWA, Feb. 22, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the completion of the sale of its shares of GrowPros MMP Inc. (“GrowPros”) to North Bud Farms Inc.  (the “Purchaser” or “North Bud”) as previously announced in Tetra’s December 21st, 2017 press release.

Transaction Details
As previously disclosed, Tetra will receive total proceeds in the amount of $350,000, including an initial $175,000 that was paid in December 2017, as well as 15,000,000 common shares of the Purchaser, representing approximately 41% of the Purchaser’s currently issued and outstanding share capital. It remains Tetra’s intention to have such shares be transferred to its shareholders as a dividend in kind on a pro-rata basis, concurrently with the proposed initial public offering of the Purchaser and listing of the shares of the Purchaser on a recognized Canadian stock exchange. The transaction is structured as a sale with a resolutory condition whereby, in the event that the initial public offering of the Purchaser is not completed prior to June 30, 2018 (or such other date as may be agreed upon by the Corporation and the Purchaser), the sale of the shares of GrowPros will be deemed to have never occurred and title to the shares of GrowPros will revert back to Tetra, and in turn GrowPros would then remain a wholly-owned subsidiary of Tetra.

As part of the transaction, North Bud has agreed to advance GrowPros’ late stage ACMPR application (submitted in November 2014) through the application process with Health Canada. In addition, the Purchaser intends to begin the phase 1 build out of a 50,000-square foot GMP grade indoor production facility in late Q1 2018. The facility is located on 130 acres of agricultural land in Venosta, Quebec (40 min north of Ottawa).  The Purchaser believes that the property can be developed into a total of 1.5 million square feet of production space. The parties intend to enter into an agreement shortly so that Tetra will be granted access to future licenced cannabis production by GrowPros, securing another source of pharmaceutical GMP quality cannabis.

The cash proceeds will be used to further strengthen Tetra’s balance sheet and, most importantly, allow the Company to focus its activities on drug development and clinical trials of its pharmaceutical business. Tetra expects this transaction to generate long-term shareholder value by ensuring another supply of cannabis with pharmaceutical GMP quality for the pipeline of products under development.

Management Statement
“This is an important transaction for Tetra and our shareholders. Not only have we monetized an asset that brings immediate cash into the business but we also have an equity stake in North Bud that we intend to distribute to our shareholders. Of course, long term, securing an additional steady supply of dried cannabis is hugely beneficial for our pharmaceutical development programs. Finally, I am very excited that North Bud will be pushing forward the ACMPR application with Health Canada. This is a great day for all parties involved!”  Says Bernard Fortier, CEO of Tetra.

About North Bud Farms:
North Bud is a partially owned subsidiary of North Bud Capital Holdings Ltd. North Bud intends to apply for a listing on a recognized Canadian stock exchange in Q2 2018. North Bud, in addition to its newly-acquired ownership of GrowPros, will be focused on GMP standardized pharma grade cannabis production as well as food grade cannabinoid infused inputs for both the international pharmaceutical market and the pending consumer goods and consumables segment of the recreational cannabis market.

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

For further information, please contact Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
1 (438) 899-7575

Tags: , , , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces the Completion of GrowPros Transaction $ACB.ca $HIP.ca $WEED.ca $CMED.ca

How to Invest in Canada’s Coming Legal #Cannabis Boom $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 4:23 PM on Tuesday, February 13th, 2018
  • In just the first six weeks of 2018, 15 of Canada’s 28 public cannabis companies have raised a combined C$1.2 billion selling securities.
  • Many investors have opted instead to focus on Canada, which has a federally legal medical cannabis program and is on the cusp of becoming the first country with federally legal access for all adults

Investing in US-based cannabis companies can be tricky, but Canadian-based companies have few of the same legal risks. (MJ_Prototype/iStock)

For those looking to invest in the legal cannabis industry, companies in the U.S. offer a quandary. Since cannabis remains federally illegal, these companies are all at risk of prosecution, a risk that may have increased earlier this year when Jeff Sessions rescinded the Cole Memo, the departmental guidance that protected states and operators as long as they adhered to the memo’s eight principles.

In just the first six weeks of 2018, 15 of Canada’s 28 public cannabis companies have raised a combined C$1.2 billion selling securities.

Many investors have opted instead to focus on Canada, which has a federally legal medical cannabis program and is on the cusp of becoming the first country with federally legal access for all adults.

What makes the Canadian cannabis sector even more interesting than its ability to service its own population legally is that many of the licensed producers (LPs) are actively involved in international markets like Europe, Australia, Latin America and Israel.

These companies are not only able to export but are also in the process of applying for licenses to operate cultivation facilities in conjunction with local investors. Germany is a particularly exciting medical cannabis market due to insurance reimbursement and distribution through traditional pharmacies.

Your Options: 28 Public Companies

Health Canada, which oversees the licensing and regulation of the Canadian cannabis industry, has approved 89 licenses, some of which have been awarded to companies holding multiple licenses. There are 28 cannabis companies that trade publicly on the Toronto Stock Exchange, the TSX Venture Exchange or the Canadian Securities Exchange. Many of these have U.S. listings as well on the OTC.

So far in just the first six weeks of 2018, 15 of these public companies have raised a combined C$1.17 billion selling securities. This access to capital is a big difference between Canadian and U.S. cannabis companies. I expect that there will be another five or so trading publicly within the next three months.

I’ve created an index for those interested in tracking the performance of this sector: the Canadian Cannabis LP Index. I break it into three different segments, including Tier 1, the largest producers, Tier 2, those that are generating sales but not at the same scale as the leaders, and Tier 3, those companies that have received their license to cultivate but aren’t yet permitted to sell. Overall, the sector has performed very well over the past two years, though it has undergone a sharp correction over the past few weeks.

The top tier includes six companies that are all generating annual sales in excess of C$16 million. These include Aurora Cannabis, Aphria, CanniMed Therapeutics, MedReleaf, CannTrust Holdings and Canopy Growth. CanniMed and Aurora Cannabis are in the process of merging, with an expected closing next month. Note that Aurora Cannabis and Canopy Growth are clients of New Cannabis Ventures, where I serve as managing partner. This article is not intended to be a recommendation of these companies or any others that I mention.

Daily Trading Exceeds C$1 Billion

With the exception of CannTrust, which trades on the Canadian Securities Exchange, each of the others trades on the Toronto Stock Exchange. The combined daily trading value of Aphria, Aurora Cannabis and Canopy Growth has been exceeding C$1 billion regularly, meaning that investors can buy and sell these names without moving the market. The other 22 publicly-traded companies also provide reasonable liquidity for the most part.

At least two exchange-traded funds (ETFs) are heavily invested in Canadian LPs.

U.S. investors interested in buying Canadian licensed producers are best off opening an account that allows them to buy and sell Canadian securities directly, but it is also possible to buy the U.S. listings.

Another alternative is to consider exchange-traded funds (ETFs). I wasn’t a fan of Horizons Marijuana Life Sciences Index ETF when it debuted in April, but it has improved. At this point, Canadian LPs make up more than 80% of the Horizon ETF’s holdings. The fund manager is launching a second ETF this week, the Emerging Marijuana Growers Index ETF, which includes smaller companies, over half of which are Canadian LPs.

High Valuations, Higher Expectations

Despite the recent decline in prices, the valuations of Canadian LPs are high relative to their current rate of sales. Still, with legalization kicking in later this year, future sales are expected to rise substantially. Canopy Growth and Aurora Cannabis have market capitalizations of about C$6 billion, followed by Aphria at C$2.8 billion, MedReleaf at C$1.9 billion, CanniMed at C$882 million and CannTrust at C$793 million. The U.S market caps are about 20% lower based on the current Canadian dollar exchange rate of $0.795.

Bottom line: Canadian cannabis companies are perhaps safer investments than those in the U.S. due to being federally legal, but they have performed very well and may be overvalued despite a recent sell-off. Investors looking to capitalize on global cannabis opportunities should consider exploring this group of companies, which currently numbers 28 and is likely to expand in the near term.

Next up: I discuss the hazards of investing in the stocks of publicly-traded producers of CBD from industrial hemp.

As an owner of New Cannabis Ventures, Alan Brochstein works with several publicly-traded and privately held cannabis companies as he discloses here. In the event he mentions a company that is a client, he will disclose it in the article as well.Source: https://www.leafly.com/news/industry/how-to-invest-in-canadas-coming-legal-cannabis-boom

Tags: , , , ,
Posted in Marijuana Company of America, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on How to Invest in Canada’s Coming Legal #Cannabis Boom $N.ca $TBP.ca $MCOA

Neptune and Tetra Bio-Pharma $TBP.ca Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:27 AM on Monday, February 12th, 2018

Logo tetrabiopharma rgb web

  • Entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products
  • Will address pain and inflammation relief applications for the natural health products and pet veterinary markets

LAVAL, QUÉBEC–(Feb. 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra”) (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.

“We are proud to partner with a company like Neptune. Their know-how in extraction, performed in a state of the art GMP facility, is a great asset to have for the cannabis medicinal/pharma oil market. This combined to Tetra’s expertise in the development of products for the prescription drug and pharma retail market, makes this partnership truly one of a kind. Leveraging our complementary expertise in research, regulatory affairs, science, formulation, and delivery forms, we intend to commercialize these new products in preparation of the forthcoming retail cannabis market in Canada, and a RX veterinary North American market,” stated Bernard Fortier, Chief Executive Officer (CEO) of Tetra.

”We are excited to partner with Tetra, a biopharmaceutical leader in the development of cannabinoid-based novel drugs and treatments. The products that will be co-developed will be supported by research as well as our unique formulation and delivery system knowledge, which are key components of our mission to deliver differentiated science-based, value-added products,” said Jim Hamilton, President and CEO of Neptune.

The veterinary health care market is expected to reach US $39.7 billion by 2021, registering a CAGR of 8.06% during 2017-2022 (the forecast period)1. Veterinary medicines are associated with treatment, diagnosis, and prevention of diseases among animals. It covers a variety of animal species, both, in domestic and wild.

1 Mordor intelligence October 2017: Veterinary Health Care Market – Growth, Trends and Forecast (2017-2022).About Neptune Technologies & Bioressources Inc.

Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Corporation formulates and develops turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extracts and formulations in high potential growth segments, such as medical and wellness cannabinoid-based products.

Neptune is also pursuing opportunities in the prescription drug markets, through its 20% investment in Acasti Pharma Inc. (“Acasti”). Acasti focuses on the research, development and commercialization of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.

The Company’s head office is located in Laval, Quebec.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking information in this press release includes, but is not limited to, information or statements about our ability to successfully develop, produce, supply, promote or generate any revenue from the sale of any cannabis-based products for medical use, as well as the results of any clinical trials associated thereto.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Information” section contained in Neptune’s latest Annual Information Form (the “AIF”), which also forms part of Neptune’s latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune’s website at www.neptunecorp.com. All forward-looking statements in this press release are made as of the date of this press release. None of Neptune and Tetra undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune’s and Tetra’s public securities filings with the Securities and Exchange Commission and/or the Canadian securities commissions, as applicable. Additional information about these assumptions and risks and uncertainties is contained in the Neptune’s AIF under “Risk Factors” or in Tetra’s MD&A under “Risk Factors”.

Neither NASDAQ, the Toronto Stock Exchange nor the TSX Venture Exchange accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Neptune Technologies & Bioressources Inc. & Tetra Bio-Pharma Inc.

Neptune Wellness Solutions
Mario Paradis
VP & CFO, Neptune
[email protected]
1.450.687.2262 x236

Investor Relations Contact (Canada)
Pierre Boucher
MaisonBrison
1.514.731.0000
[email protected]

Investor Relations Contact (U.S.)
Ed McGregor/Jody Burfening
LHA, IR
1.212.838.3777
[email protected]

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
O: (438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

Tags: , , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Neptune and Tetra Bio-Pharma $TBP.ca Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »